• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Are Metformin or Statins Associated with Increased Risk for Ovarian Cancer in Women with Type 2 Diabetes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • There are previous reports of reduced risk of cancers, including ovarian cancer in individuals with type 2 diabetes (T2D) being managed with metformin
  • Statin use has also been associated with reduced risk of cancer in some papers while there are other reports of women with T2D having an increased incidence of various cancers, including ovarian cancer especially in those treated with insulin
  • Many of these studies had methodological flaws, including smaller sample sizes
  • Urpilainen et al. (BJOG, 2018) assessed the impact of metformin and statin use on rates of ovarian cancer in women with type 2 diabetes (T2D)

METHODS:

The authors used 2 different study designs

Cohort Study

  • Data was obtained from the diabetes database (FinDM) combining information from several Finnish nationwide registers
  • Women were over 40 years old and diagnosed with T2D
  • Hazard ratio (HR) was used to determine the relationship between ovarian cancer and ever use of
    • Metformin
    • Insulin
    • Other anti-diabetic medication
    • Statins

Case Control Study

  • 20 controls were matched to each case of ovarian cancer
  • Conditional logistic regression was used to estimate HRs in relation to medication use and cumulative use of different medications

RESULTS:

  • Data was collected from 137,643 women (mean follow up 5.4 years)
    • 303 women were diagnosed with ovarian cancer
    • Incidence of ovarian cancer was highest in women age 60-69 years
  • For the case control study, 6060 controls were matched to the 303 cases of ovarian cancer based on age and T2D duration
  • Compared with other forms of oral anti-diabetic medication, metformin was not found to be associated with the incidence of ovarian cancer
    • HR 1.02; 95% CI, 0.72-1.45
  • There was also no evidence that statins affect the incidence of ovarian cancer
    • HR 0.99, 95% CI: 0.78-1.25
  • In the nested case-control analysis, the results were similar and no associations were found between metformin or statins and ovarian cancer
  • There was no increased risk of ovarian cancer in women with T2D treated with insulin

CONCLUSION:

  • There was no measured association between the use of metformin or statins and risk for ovarian cancer in women with T2D

Learn More – Primary Sources:

The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study.

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Update from the ACP: New Hemoglobin A1c Targets for Type 2 Diabetes Mellitus
ACOG and SMFM Both Release Guidance on Gestational Diabetes – Insulin vs Metformin for First-Line Therapy?
Results of the DiRECT Trial: Can Weight Loss in a Primary Care Setting Achieve Remission of Type 2 Diabetes?
USPSTF Releases Final Recommendation On Ovarian Cancer Screening

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site